CreativeOne Wealth LLC Invests $92,000 in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

CreativeOne Wealth LLC acquired a new stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,750 shares of the company’s stock, valued at approximately $92,000.

Other hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new position in Mineralys Therapeutics during the fourth quarter valued at approximately $41,000. CWM LLC grew its holdings in shares of Mineralys Therapeutics by 120.0% during the 4th quarter. CWM LLC now owns 5,891 shares of the company’s stock valued at $51,000 after purchasing an additional 3,213 shares during the last quarter. SG Americas Securities LLC purchased a new position in Mineralys Therapeutics in the 4th quarter worth $87,000. Cornercap Investment Counsel Inc. bought a new stake in Mineralys Therapeutics in the fourth quarter worth $191,000. Finally, Federated Hermes Inc. lifted its stake in Mineralys Therapeutics by 8.3% in the third quarter. Federated Hermes Inc. now owns 22,293 shares of the company’s stock worth $212,000 after purchasing an additional 1,700 shares during the last quarter. Institutional investors own 84.46% of the company’s stock.

Mineralys Therapeutics Trading Down 0.2 %

Shares of NASDAQ MLYS opened at $12.20 on Friday. Mineralys Therapeutics, Inc. has a 1 year low of $5.85 and a 1 year high of $17.44. The company’s 50-day moving average is $12.72 and its 200 day moving average is $11.05.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Thursday, March 21st. The company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.24. On average, research analysts anticipate that Mineralys Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Lifesci Capital reaffirmed an “outperform” rating on shares of Mineralys Therapeutics in a research note on Tuesday, March 26th. The Goldman Sachs Group started coverage on Mineralys Therapeutics in a research note on Tuesday, April 2nd. They issued a “buy” rating and a $30.00 price target on the stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.